Cooper Companies [COO] vs West Pharmaceutical [WST] Detailed Stock Comparison
Cooper Companies
NASDAQ
Loading...
West Pharmaceutical
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cooper Companies wins in 9 metrics, West Pharmaceutical wins in 10 metrics, with 0 ties. West Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cooper Companies | West Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 34.54 | 40.74 | Cooper Companies |
| Price-to-Book Ratio | 1.68 | 6.69 | Cooper Companies |
| Debt-to-Equity Ratio | 29.67 | 10.52 | West Pharmaceutical |
| PEG Ratio | -5.78 | 2.06 | Cooper Companies |
| EV/EBITDA | 14.70 | 24.57 | Cooper Companies |
| Profit Margin (TTM) | 10.08% | 16.48% | West Pharmaceutical |
| Operating Margin (TTM) | 16.57% | 20.87% | West Pharmaceutical |
| EBITDA Margin (TTM) | 16.57% | 20.87% | West Pharmaceutical |
| Return on Equity | 5.01% | 17.72% | West Pharmaceutical |
| Return on Assets (TTM) | 3.79% | 10.53% | West Pharmaceutical |
| Free Cash Flow (TTM) | $288.10M | $276.40M | Cooper Companies |
| Dividend Yield | N/A | 0.38% | N/A |
| 1-Year Return | -34.32% | -9.10% | West Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 3.46 | 6.62 | Cooper Companies |
| Enterprise Value | $16.36B | $19.40B | West Pharmaceutical |
| EV/Revenue Ratio | 4.04 | 6.55 | Cooper Companies |
| Gross Profit Margin (TTM) | 65.26% | 35.73% | Cooper Companies |
| Revenue per Share (TTM) | $20 | $41 | West Pharmaceutical |
| Earnings per Share (Diluted) | $2.04 | $6.69 | West Pharmaceutical |
| Beta (Stock Volatility) | 1.02 | 1.07 | Cooper Companies |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Cooper Companies vs West Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cooper Companies | -0.50% | 3.61% | 1.92% | -4.34% | -4.37% | -22.67% |
| West Pharmaceutical | -1.65% | 2.98% | 5.89% | 21.04% | 33.06% | -18.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cooper Companies | -34.32% | 12.77% | -20.72% | 94.32% | 455.55% | 291.68% |
| West Pharmaceutical | -9.10% | 8.30% | -8.21% | 375.72% | 1,389.28% | 1,825.79% |
News Based Sentiment: Cooper Companies vs West Pharmaceutical
Cooper Companies
News based Sentiment: MIXED
October presented a mixed bag for Cooper Companies, with a negative analyst rating offset by positive earnings and insider activity. The revised guidance and lowered price targets suggest a more cautious outlook, while the stock repurchase program and institutional support offer some positive signals. This creates a complex investment picture requiring careful consideration.
West Pharmaceutical
News based Sentiment: POSITIVE
West Pharmaceutical Services reported a strong Q2, exceeding expectations and reaffirming guidance, which fueled analyst optimism and increased price targets. While valuation remains a concern and operational challenges exist, the overall narrative is positive, suggesting continued growth potential and making it a compelling investment option.
Performance & Financial Health Analysis: Cooper Companies vs West Pharmaceutical
| Metric | COO | WST |
|---|---|---|
| Market Information | ||
| Market Cap | $14.01B | $19.60B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 2,777,290 | 658,600 |
| 90 Day Avg. Volume | 3,351,933 | 619,057 |
| Last Close | $70.11 | $268.07 |
| 52 Week Range | $61.78 - $109.37 | $187.43 - $352.33 |
| % from 52W High | -35.90% | -23.92% |
| All-Time High | $115.90 (Aug 30, 2021) | $475.35 (Sep 06, 2021) |
| % from All-Time High | -39.51% | -43.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.09% |
| Quarterly Earnings Growth | -0.06% | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.16% |
| Operating Margin (TTM) | 0.17% | 0.21% |
| Return on Equity (TTM) | 0.05% | 0.18% |
| Debt to Equity (MRQ) | 29.67 | 10.52 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $42.02 | $40.74 |
| Cash per Share (MRQ) | $0.63 | $7.09 |
| Operating Cash Flow (TTM) | $816.30M | $676.70M |
| Levered Free Cash Flow (TTM) | $276.21M | $207.85M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.38% |
| Last 12-Month Dividend | $0.00 | $0.83 |
Valuation & Enterprise Metrics Analysis: Cooper Companies vs West Pharmaceutical
| Metric | COO | WST |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 34.54 | 40.74 |
| Forward P/E | 17.27 | 36.24 |
| PEG Ratio | -5.78 | 2.06 |
| Price to Sales (TTM) | 3.46 | 6.62 |
| Price to Book (MRQ) | 1.68 | 6.69 |
| Market Capitalization | ||
| Market Capitalization | $14.01B | $19.60B |
| Enterprise Value | $16.36B | $19.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.04 | 6.55 |
| Enterprise to EBITDA | 14.70 | 24.57 |
| Risk & Other Metrics | ||
| Beta | 1.02 | 1.07 |
| Book Value per Share (MRQ) | $42.02 | $40.74 |
Financial Statements Comparison: Cooper Companies vs West Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | COO | WST |
|---|---|---|
| Revenue/Sales | $1.00B | $766.50M |
| Cost of Goods Sold | $323.20M | $492.60M |
| Gross Profit | $679.10M | $273.90M |
| Research & Development | $45.50M | $19.10M |
| Operating Income (EBIT) | $184.80M | $158.90M |
| EBITDA | $262.50M | $203.40M |
| Pre-Tax Income | $144.50M | $157.00M |
| Income Tax | $56.80M | $30.20M |
| Net Income (Profit) | $87.70M | $131.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | COO | WST |
|---|---|---|
| Cash & Equivalents | $116.20M | $509.70M |
| Total Current Assets | $2.13B | $1.68B |
| Total Current Liabilities | $1.01B | $604.60M |
| Long-Term Debt | $2.53B | $282.40M |
| Total Shareholders Equity | $8.29B | $2.93B |
| Retained Earnings | $7.46B | $4.14B |
| Property, Plant & Equipment | N/A | $3.28B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | COO | WST |
|---|---|---|
| Operating Cash Flow | $261.80M | $177.40M |
| Capital Expenditures | $-78.10M | N/A |
| Free Cash Flow | $18.10M | $101.90M |
| Debt Repayment | $-714.60M | $-300,000 |
| Common Stock Repurchase | N/A | $-500,000 |
Short Interest & Institutional Ownership Analysis
| Metric | COO | WST |
|---|---|---|
| Shares Short | 6.24M | 1.68M |
| Short Ratio | 1.85 | 2.92 |
| Short % of Float | 0.03% | 0.03% |
| Average Daily Volume (10 Day) | 2,777,290 | 658,600 |
| Average Daily Volume (90 Day) | 3,351,933 | 619,057 |
| Shares Outstanding | 199.60M | 72.30M |
| Float Shares | 197.50M | 71.41M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.04% | 0.98% |
Dividend Analysis & Yield Comparison: Cooper Companies vs West Pharmaceutical
| Metric | COO | WST |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $0.83 |
| Last 12-Month Dividend Yield | N/A | 0.38% |
| 3-Year Avg Annual Dividend | $0.01 | $0.79 |
| 3-Year Avg Dividend Yield | 0.01% | 0.07% |
| 3-Year Total Dividends | $0.03 | $2.37 |
| Ex-Dividend Date | Jul 26, 2023 | Apr 30, 2025 |